Applicant, as named in the Orange Book

Day One Biopharms

Next listed expiry: Ojemda on 23 Jun 2035. 2 products with live protection, 0 without.

Products with listed protection

Drug	Ingredient	NDA	Earliest generic entry	Basis
Ojemda tovorafenib	tovorafenib	217700	23 Jun 2035	patent
Ojemda tovorafenib	tovorafenib	218033	23 Jun 2035	patent

No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.